Share price corrections and downward volatility in Avacta Group plc are often driven by the inherent cash-burn profiles and clinical milestone risks typical of early-stage oncology and biotechnology firms. Delays in pipeline readouts, broader macroeconomic shifts affecting small-cap growth equities on the Alternative Investment Market (AIM), and equity capital raises to fund ongoing clinical trials can create temporary selling pressure.